Total liabilities · 2020–2025
Monte Rosa Therapeutics total liabilities
$216M−0.1% · FY2025
Monte Rosa Therapeutics (GLUE) reported $216M in total liabilities for fiscal 2025, −0.1% year on year.
Total liabilities — Total liabilities is everything the company owes at the balance-sheet date — debt, payables, deferred revenue and provisions together. Where a filer does not tag it, we calculate it as total assets minus total equity and label the figure as calculated.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2020–2025 compound annual growth +48.0%
Total liabilities at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Monte Rosa Therapeutics total liabilities |url=https://companiesranked.com/en/company/monte-rosa-therapeutics/total-liabilities |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Monte Rosa Therapeutics total liabilities. CompaniesRanked. https://companiesranked.com/en/company/monte-rosa-therapeutics/total-liabilitiesBibTeX
@misc{companiesranked-en-company-monte-rosa-therapeutics-total-liabilities-2026,
author = {{CompaniesRanked}},
title = {{Monte Rosa Therapeutics total liabilities}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/monte-rosa-therapeutics/total-liabilities}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-Q · 0001193125-26-336711 · August 6, 2026
{{cite web |title=Monte Rosa Therapeutics total liabilities — 10-Q (0001193125-26-336711) |url=https://www.sec.gov/Archives/edgar/data/1826457/000119312526336711/glue-20260630.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-08-06}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.